Brensocatib faces ICER spotlight with strong case for clinical and economic value
ICER pegs an ~$88K benchmark for brensocatib and spotlights evidence gaps shaping NCFB access.
Shajini
Novo’s unsolicited bid for Metsera challenges Pfizer pact
Novo’s unsolicited Metsera bid could upend Pfizer pact and reshape the GLP-1 race.
Reimbursement Series: CMS and Europe Reimbursement Pathway Accelerates Innovation
In a transformative week for market access, the CMS and Europe reimbursement pathway expansion delivered several pivotal coverage and pricing decisions reshaping patient access across cardiovascular, hepatic, and oncology therapies. From CMS’s national determinations on breakthrough devices to European HTA approvals in rare disease and cancer, these developments underscore a growing transatlantic alignment between regulators … Read more
Baird Medical Secures Pivotal Reimbursement Win for MWA
Successful reimbursement milestone strengthens device adoption and access strategy.
UK Government Unlocks Game-Changing Drug Pricing Strategy
UK braces as drug pricing shifts dramatically in market access landscape.
Reimbursement Series: Anchors Affordable Breakthroughs – AIFA and TLV Expand European Coverage
Sweden expands reimbursement decisions driving biotech access and patient impact.
NICE Secures Breakthrough HTA Decision for Prostate Cancer
NICE issues breakthrough HTA decision on Bayer’s prostate cancer therapy.
Poland Makes Historic Leap in Healthcare: Record Number of New Therapies Now Reimbursed
Poland’s Ministry of Health has announced its largest-ever reimbursement list update
FDA’s BsUFA III Framework: What It Means for Biosimilar Sponsors
FDA defines biosimilar PAS & CBE under BsUFA III
Focus Brief: Market Access Weekly September 1 to 7, 2025
Global market access shifts: HTA speed, UK pricing, digital disruption.